title: Functional genomics and the development of pathogenesis-targeted therapies for Kaposi's sarcoma.
abstract: Kaposi's sarcoma (KS) is a multifocal angioproliferative disorder affecting the skin, mucosa and viscera of individuals infected with human herpesvirus-8 (HHV-8; also Kaposi's sarcoma-associated herpesvirus [KSHV]). KS is the most common neoplasm in AIDS patients; the clinical outcome of AIDS-KS is significantly improved by highly active antiretroviral therapy (HAART). However, in Africa, where the severest manifestations of KS occur, there is limited access to these and other effective but expensive drugs. Here we present a review of current efforts to identify novel therapeutic targets for the treatment of KS using functional genomics, with recommendations regarding the development of economically feasible treatments for use in Africa.
authors: Oregon Health and Science University, Vaccine and Gene Therapy Institute, Portland, Oregon 97201, USA.
authors: Shane C
authors: SC
authors: McAllister
authors: Klaus
authors: K
authors: Früh
authors: Ashlee V
authors: AV
authors: Moses
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D023281:Genomics; D051547:Heme Oxygenase-1 / Q000037:antagonists & inhibitors; D019288:Herpesvirus 8, Human; D006801:Humans; D000068877:Imatinib Mesylate; D008652:Mesoporphyrins / Q000627:therapeutic use; D008954:Models, Biological; D016376:Oligonucleotides, Antisense / Q000494:pharmacology; D010879:Piperazines / Q000627:therapeutic use; D019009:Proto-Oncogene Proteins c-kit / Q000378:metabolism; D011743:Pyrimidines / Q000627:therapeutic use; D012514:Sarcoma, Kaposi / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology / Q000821:virology*
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D008652:Mesoporphyrins; D016376:Oligonucleotides, Antisense; D010879:Piperazines; D011743:Pyrimidines; C031468:mesoporphyrin IX; D000068877:Imatinib Mesylate; D051547:Heme Oxygenase-1; D019009:Proto-Oncogene Proteins c-kit